FTD/TPI-话题@MedSci

#FTD/TPI#

4篇内容 | 813人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2172074, encodeId=e6ca21e2074a0, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a> <a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a> <a href='/topic/show?id=9841e70051' target=_blank style='color:#2F92EE;'>#FTD/TPI#</a>, objectTitle=读书报告 | KRAS突变位点可预测FTD/TPI治疗转移性结直肠癌的生存获益风险, objectType=article, longId=802950, objectId=d996802950f5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=d996802950f5, replyNumber=0, likeNumber=43, createdTime=2023-11-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d996802950f5, moduleTitle=读书报告 | KRAS突变位点可预测FTD/TPI治疗转移性结直肠癌的生存获益风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d996802950f5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1700401, encodeId=f6731e0040119, content=<a href='/topic/show?id=9841e70051' target=_blank style='color:#2F92EE;'>#FTD/TPI#</a>, objectTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, objectType=article, longId=293627, objectId=c7ac29362eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac29362eb8, replyNumber=0, likeNumber=45, createdTime=2022-06-08, rootId=0, userName=mhm299, userId=38a330078104, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac29362eb8, moduleTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac29362eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700399, encodeId=fe091e0039908, content=<a href='/topic/show?id=9841e70051' target=_blank style='color:#2F92EE;'>#FTD/TPI#</a>, objectTitle=The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比, objectType=article, longId=218080, objectId=e0d821808039, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d821808039, replyNumber=0, likeNumber=38, createdTime=2022-07-27, rootId=0, userName=mhm299, userId=38a330078104, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d821808039, moduleTitle=The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d821808039)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700400, encodeId=5c831e0040065, content=<a href='/topic/show?id=9841e70051' target=_blank style='color:#2F92EE;'>#FTD/TPI#</a>, objectTitle=Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响, objectType=article, longId=219546, objectId=ba20219546f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba20219546f3, replyNumber=0, likeNumber=35, createdTime=2022-08-04, rootId=0, userName=mhm299, userId=38a330078104, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba20219546f3, moduleTitle=Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba20219546f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700398, encodeId=bb951e00398cc, content=<a href='/topic/show?id=9841e70051' target=_blank style='color:#2F92EE;'>#FTD/TPI#</a>, objectTitle=Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性, objectType=article, longId=191573, objectId=25001915e376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25001915e376, replyNumber=0, likeNumber=42, createdTime=2020-09-20, rootId=0, userName=mhm299, userId=38a330078104, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25001915e376, moduleTitle=Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25001915e376)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FTD/TPI

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#KRAS突变# #转移性结直肠癌# #FTD/TPI#

读书报告 | KRAS突变位点可预测FTD/TPI治疗转移性结直肠癌的生存获益风险

2023-11-30发表于上海

mhm299 (审核中...)

前往app查看评论内容

#FTD/TPI#

Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性

2022-06-08

mhm299 (审核中...)

前往app查看评论内容

#FTD/TPI#

The Oncologist： FTD/TPI和瑞戈非尼治疗晚期结直肠癌患者疗效对比

2022-07-27

mhm299 (审核中...)

前往app查看评论内容

#FTD/TPI#

Front Oncol：原发性肿瘤位置(PTL)对于mCRC患者后线使用REG或FTD/TPI治疗的影响

2022-08-04

mhm299 (审核中...)

前往app查看评论内容

#FTD/TPI#

Clin cancer res：FTD/TPI+伊立替康+贝伐单抗联合治疗晚期消化道肿瘤的疗效和安全性

2020-09-20

科室
- - 订阅+
  - 更多科室
工具
服务